Carrington Laboratories, Inc. Subsidiary DelSite Biotechnologies, Inc. Extends Commercial Evaluation License Agreement With National Institutes of Health (NIH) for Typhoid Vaccine
Published: May 16, 2008
IRVING, Texas, May 16, 2008 (PRIME NEWSWIRE) -- Carrington Laboratories, Inc. (OTCBB:CARN) today announced its wholly-owned subsidiary, DelSite Biotechnologies, Inc., has extended its Commercial Evaluation License from NIH (National Institutes of Health) for evaluating a novel synthetic typhoid polysaccharide vaccine technology with DelSite's proprietary high-molecular-weight ionic polysaccharide, GelSite(r) polymer. DelSite Biotechnologies, Inc. is developing and commercializing GelSite polymer as a controlled-release drug delivery technology for protein/peptide therapeutics and vaccine products. This synthetic typhoid vaccine represents a unique and important application of the GelSite polymer.